JP7585045B2 - 瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達 - Google Patents

瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達 Download PDF

Info

Publication number
JP7585045B2
JP7585045B2 JP2020564323A JP2020564323A JP7585045B2 JP 7585045 B2 JP7585045 B2 JP 7585045B2 JP 2020564323 A JP2020564323 A JP 2020564323A JP 2020564323 A JP2020564323 A JP 2020564323A JP 7585045 B2 JP7585045 B2 JP 7585045B2
Authority
JP
Japan
Prior art keywords
composition
hydrogel
faki
wounds
fak inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564323A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019222520A5 (enExample
JP2021524849A (ja
Inventor
シー． ガートナー，ジェフリー
クォン，スン，ヒョン
アハマッド，モハメッド，イナーヤトゥッラー ナズィール
ジャヤクマール ラジャダス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2021524849A publication Critical patent/JP2021524849A/ja
Publication of JPWO2019222520A5 publication Critical patent/JPWO2019222520A5/ja
Priority to JP2024102853A priority Critical patent/JP2024123220A/ja
Application granted granted Critical
Publication of JP7585045B2 publication Critical patent/JP7585045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/18—Materials or treatment for tissue regeneration for hair reconstruction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020564323A 2018-05-16 2019-05-16 瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達 Active JP7585045B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024102853A JP2024123220A (ja) 2018-05-16 2024-06-26 瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862672513P 2018-05-16 2018-05-16
US62/672,513 2018-05-16
US201962848515P 2019-05-15 2019-05-15
US62/848,515 2019-05-15
PCT/US2019/032697 WO2019222520A1 (en) 2018-05-16 2019-05-16 Controlled hydrogel delivery of focal adhesion kinase inhibitor for decreased scar formation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024102853A Division JP2024123220A (ja) 2018-05-16 2024-06-26 瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達

Publications (3)

Publication Number Publication Date
JP2021524849A JP2021524849A (ja) 2021-09-16
JPWO2019222520A5 JPWO2019222520A5 (enExample) 2022-05-23
JP7585045B2 true JP7585045B2 (ja) 2024-11-18

Family

ID=68540759

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564323A Active JP7585045B2 (ja) 2018-05-16 2019-05-16 瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達
JP2024102853A Pending JP2024123220A (ja) 2018-05-16 2024-06-26 瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024102853A Pending JP2024123220A (ja) 2018-05-16 2024-06-26 瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達

Country Status (8)

Country Link
US (1) US12178940B2 (enExample)
EP (1) EP3793589B1 (enExample)
JP (2) JP7585045B2 (enExample)
CN (1) CN112384238A (enExample)
AU (2) AU2019269608B2 (enExample)
CA (1) CA3100352A1 (enExample)
ES (1) ES2980620T3 (enExample)
WO (1) WO2019222520A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024123220A (ja) * 2018-05-16 2024-09-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4126223A4 (en) * 2020-03-26 2024-04-24 The Board of Trustees of the Leland Stanford Junior University Methods for tissue regeneration and kits therefor
WO2022191812A1 (en) * 2021-03-08 2022-09-15 National Cheng Kung University Method of facilitating wound-induced hair follicle neogenesis, tissue regeneration and reducing wound stiffness
AU2022318736A1 (en) * 2021-07-30 2023-11-16 The Board Of Trustees Of The Leland Stanford Junior University Mechanotransduction disruption mediation in skin grafting methods and compositions for use in practicing the same
EP4661921A1 (en) * 2023-02-24 2025-12-17 Tautona Group Research And Development Company, L.L.C. Wound dressing assembly
WO2025122385A1 (en) * 2023-12-08 2025-06-12 Purinomia Biotech, Inc. Methods and compositions for reducing scar formation and treating dermatological wounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003190206A (ja) 2001-12-28 2003-07-08 Life Kea Giken Kk 創傷保護剤とその製造方法
JP2007513693A (ja) 2003-12-11 2007-05-31 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚創傷の処置のための方法および組成物
WO2012063947A1 (ja) 2010-11-12 2012-05-18 日産化学工業株式会社 脂質ペプチド型ゲル化剤と高分子化合物とを含有するゲルシート
US20130165463A1 (en) 2011-12-09 2013-06-27 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of focal adhesion kinase for control of scar tissue formation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101499080B1 (ko) 2006-08-03 2015-03-06 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 반흔 및/또는 켈로이드의 치료 또는 예방을 위한 디바이스 및 붕대와 그것을 위한 방법 및 키트
US9636362B2 (en) * 2010-03-04 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Pullulan regenerative matrix
US20140072613A1 (en) 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
AU2019269608B2 (en) * 2018-05-16 2025-04-03 The Board Of Trustees Of The Leland Stanford Junior University Controlled hydrogel delivery of focal adhesion kinase inhibitor for decreased scar formation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003190206A (ja) 2001-12-28 2003-07-08 Life Kea Giken Kk 創傷保護剤とその製造方法
JP2007513693A (ja) 2003-12-11 2007-05-31 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚創傷の処置のための方法および組成物
WO2012063947A1 (ja) 2010-11-12 2012-05-18 日産化学工業株式会社 脂質ペプチド型ゲル化剤と高分子化合物とを含有するゲルシート
US20130165463A1 (en) 2011-12-09 2013-06-27 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of focal adhesion kinase for control of scar tissue formation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. Invest. Dermatol. (May-15 2018) vol.138, issue 11, p.2452-2460
Tissue Eng, Part A (2011) vol.17, no.5-6, p.631-644
Wound Repair Regen. (2017) vol.25, issue 4, p.A7(右欄第１演題)
Wound Repair Regen. (Arp 2018) vol.26, issue 1, p.A33(P.FS08)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024123220A (ja) * 2018-05-16 2024-09-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達

Also Published As

Publication number Publication date
AU2019269608B2 (en) 2025-04-03
AU2025205095A1 (en) 2025-07-24
CN112384238A (zh) 2021-02-19
CA3100352A1 (en) 2019-11-21
AU2019269608A1 (en) 2020-11-26
ES2980620T3 (es) 2024-10-02
JP2024123220A (ja) 2024-09-10
WO2019222520A1 (en) 2019-11-21
US20210361833A1 (en) 2021-11-25
EP3793589A4 (en) 2022-01-26
EP3793589B1 (en) 2024-05-01
US12178940B2 (en) 2024-12-31
JP2021524849A (ja) 2021-09-16
EP3793589A1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
JP7585045B2 (ja) 瘢痕形成の減少の為の接着斑キナーゼ阻害剤の制御されたヒドロゲル送達
Shi et al. Naturally derived dual dynamic crosslinked multifunctional hydrogel for diabetic wound healing
JP7486404B2 (ja) 羊膜粉末ならびに創傷治癒および組織工学構築物におけるその使用
Chopra et al. Strategies and therapies for wound healing: a review
JP6042815B2 (ja) 生物医学的応用のためのアルギン酸塩及びヒアルロン酸を用いる抗癒着性バリア膜
Ma et al. Controlled delivery of a focal adhesion kinase inhibitor results in accelerated wound closure with decreased scar formation
US8475812B2 (en) Gelatin sponge comprising an active ingredient, its preparation and use
Thu et al. Alginate based bilayer hydrocolloid films as potential slow-release modern wound dressing
US6132759A (en) Medicaments containing gelatin cross-linked with oxidized polysaccharides
US6458386B1 (en) Medicaments based on polymers composed of methacrylamide-modified gelatin
US9636362B2 (en) Pullulan regenerative matrix
WO2021015631A9 (en) Multilayer nanofibres with bioactive compositions for wound healing management
US11622892B2 (en) Methods of making bioactive collagen wound care dressings
AU2008219065A1 (en) Hemostatic compositions and therapeutic regimens
CN112107723A (zh) 医用水性黏胶及其使用方法
WO1994017840A1 (en) Pharmaceutical compositions comprising a spongy material consisting of ester derivatives of hyaluronic acid combined with other pharmacologically active substances
Zhao et al. Biodegradable multifunctional hyaluronic acid hydrogel microneedle band-aids for accelerating skin wound healing
CN111905144B (zh) 一种可生物降解的晶胶敷料及其制备方法和应用
CN105007841A (zh) 用于大量出血的冻干纤维蛋白封闭剂
RU2226406C1 (ru) Гемостатическая, антисептическая и ранозаживляющая губка
CN1321702C (zh) 外伤急救敷片
US20100056452A1 (en) Angiogenesis-promoting substrate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240626

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241106

R150 Certificate of patent or registration of utility model

Ref document number: 7585045

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150